BNP Paribas Financial Markets
HRTX icon

BNP Paribas Financial Markets’s Heron Therapeutics HRTX Stock Holding History

BNP Paribas Financial Markets’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26K Sell
32,454
-416
-1% -$482 ﹤0.01% 5006
2025
Q4 		$42.7K Sell
32,870
-345,718
-91% -$427K ﹤0.01% 4758
2025
Q3 		$477K Buy
378,588
+72,745
+24% +$115K ﹤0.01% 3566
2025
Q2 		$633K Buy
305,843
+31,898
+12% +$65.1K ﹤0.01% 3178
2025
Q1 		$603K Sell
273,945
-3,399
-1% -$6.6K ﹤0.01% 3073
2024
Q4 		$424K Buy
277,344
+1,398
+0.5% +$2.27K ﹤0.01% 3394
2024
Q3 		$549K Buy
275,946
+92,425
+50% +$221K ﹤0.01% 2818
2024
Q2 		$642K Buy
183,521
+132,225
+258% +$406K ﹤0.01% 2527
2024
Q1 		$142K Buy
51,296
+22,904
+81% +$57.6K ﹤0.01% 3346
2023
Q4 		$48.3K Sell
28,392
-32,258
-53% -$35.5K ﹤0.01% 3573
2023
Q3 		$62.5K Sell
60,650
-48,719
-45% -$69.3K ﹤0.01% 3424
2023
Q2 		$127K Buy
109,369
+65,914
+152% +$118K ﹤0.01% 3183
2023
Q1 		$65.6K Buy
43,455
+20,358
+88% +$51K ﹤0.01% 3393
2022
Q4 		$57.7K Sell
23,097
-210,443
-90% -$678K ﹤0.01% 3388
2022
Q3 		$986K Buy
233,540
+198,924
+575% +$778K ﹤0.01% 2499
2022
Q2 		$96.6K Sell
34,616
-222,969
-87% -$895K ﹤0.01% 3362
2022
Q1 		$1.47M Buy
257,585
+104,604
+68% +$765K ﹤0.01% 2051
2021
Q4 		$1.4M Buy
152,981
+136,197
+811% +$1.39M ﹤0.01% 2349
2021
Q3 		$179K Buy
16,784
+13,339
+387% +$162K ﹤0.01% 3079
2021
Q2 		$53.5K Sell
3,445
-8,007
-70% -$127K ﹤0.01% 3237
2021
Q1 		$186K Buy
11,452
+34
+0.3% +$606 ﹤0.01% 3079
2020
Q4 		$242K Sell
11,418
-9,221
-45% -$160K ﹤0.01% 2787
2020
Q3 		$306K Buy
20,639
+10,056
+95% +$157K ﹤0.01% 2499
2020
Q2 		$156K Sell
10,583
-94,014
-90% -$1.54M ﹤0.01% 2592
2020
Q1 		$1.23M Buy
104,597
+92,744
+782% +$1.74M ﹤0.01% 1783
2019
Q4 		$279K Sell
11,853
-1,106
-9% -$24.5K ﹤0.01% 2804
2019
Q3 		$240K Buy
12,959
+3,490
+37% +$64.2K ﹤0.01% 2658
2019
Q2 		$176K Sell
9,469
-6,159
-39% -$123K ﹤0.01% 2700
2019
Q1 		$382K Buy
15,628
+14,324
+1,098% +$375K ﹤0.01% 2273
2018
Q4 		$33.8K Sell
1,304
-2,126
-62% -$58.5K ﹤0.01% 2905
2018
Q3 		$109K Buy
3,430
+86
+3% +$3.2K ﹤0.01% 2696
2018
Q2 		$130K Sell
3,344
-7,885
-70% -$251K ﹤0.01% 2657
2018
Q1 		$310K Buy
11,229
+1,761
+19% +$39.9K ﹤0.01% 2520
2017
Q4 		$171K Buy
9,468
+4,871
+106% +$79.4K ﹤0.01% 3039
2017
Q3 		$74.2K Sell
4,597
-307
-6% -$4.82K ﹤0.01% 2932
2017
Q2 		$67.9K Buy
4,904
+4,453
+987% +$64.5K ﹤0.01% 3024
2017
Q1 		$6.76K Sell
451
-103
-19% -$1.43K ﹤0.01% 3247
2016
Q4 		$7.26K Sell
554
-1,609
-74% -$25.2K ﹤0.01% 3584
2016
Q3 		$37.3K Buy
2,163
+928
+75% +$17.2K ﹤0.01% 2569
2016
Q2 		$22.3K Buy
+1,235
New +$24.1K ﹤0.01% 2541
2016
Q1 		– Sell
-7,076
Closed -$189K – 2850
2015
Q4 		$189K Buy
7,076
+963
+16% +$25.8K ﹤0.01% 1975
2015
Q3 		$149K Buy
6,113
+4,062
+198% +$135K ﹤0.01% 2146
2015
Q2 		$63.9K Buy
2,051
+1,505
+276% +$28.3K ﹤0.01% 2340
2015
Q1 		$7.94K Buy
+546
New +$6.16K ﹤0.01% 2877
2014
Q4 		– Sell
-1,624
Closed -$13.5K – 2536
2014
Q3 		$13.5K Buy
+1,624
New +$15.1K ﹤0.01% 3423

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

BNP Paribas Financial Markets's HRTX Position: Q1 2026 in Review

BNP Paribas Financial Markets reduced its Heron Therapeutics (HRTX) stake by 1.3% in Q1 2026, selling an estimated $482 and leaving 32,454 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #5006.

BNP Paribas Financial Markets first reported a position in HRTX in Q3 2014 and has held it in 45 quarters since. The position peaked at $1.47M in Q1 2022. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • BNP Paribas Financial Markets held 32,454 shares of Heron Therapeutics worth $26K as of Q1 2026.
  • BNP Paribas Financial Markets sold 416 Heron Therapeutics shares in Q1 2026, an estimated $482.
  • Heron Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5006 holding.
  • BNP Paribas Financial Markets first reported a position in Heron Therapeutics in Q3 2014 and has held it in 45 quarters since.
  • BNP Paribas Financial Markets's Heron Therapeutics position peaked at $1.47M in Q1 2022.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.